

11/PRTS

## SPECIFICATION

HUMAN CELL LINE SHOWING STABLE EXPRESSION  
OF CYTOCHROMES P450

5

## FIELD OF THE INVENTION

This invention relates to the following features.

1. A cell line derived from human hepatic carcinoma  
10 capable of stably expressing human cytochromes P450.

2. (1) A method for analyzing an enzyme participating  
in the metabolism of a xenobiotic and/or an endogenous  
substrate, (2) a method for analyzing a metabolic pathway  
of a xenobiotic and/or an endogenous substrate, (3) a method  
15 for analyzing a chemical structure of the metabolite of a  
xenobiotic and/or an endogenous substrate, (4) a method for  
preparing the metabolite of a xenobiotic and/or an  
endogenous substrate, (5) a method for analyzing inhibition  
of the metabolizing enzyme for a xenobiotic and/or an  
20 endogenous substrate, (6) a method for analyzing an  
accelerated activity of the metabolizing enzyme for a  
xenobiotic and/or an endogenous substrate, (7) a method for  
analyzing expression of cytotoxicity by the metabolism of  
a xenobiotic and/or an endogenous substrate, (8) a method  
25 for analyzing expression of genotoxicity by the metabolism  
of a xenobiotic and/or an endogenous substrate, (9) a method  
for analyzing expression of carcinogenicity by the  
metabolism of a xenobiotic and/or endogenous substrate,  
(10) a method for analyzing mutagenicity by the metabolism  
30 of a xenobiotic and/or an endogenous substrate, (11) a  
method for analyzing expression of hepatotoxicity by the  
metabolism of a xenobiotic and/or an endogenous substrate,  
and (12) a method for analyzing a xenobiotic and/or an  
endogenous substrate that acts on the liver, each method  
35 comprising use of the cell line according to (1).

3. (1) A method for screening a substance capable of

10009158-102501

inhibiting a xenobiotic and/or an endogenous substrate, (2) a method for screening a substance capable of accelerating the activity of a metabolizing enzyme for a xenobiotic and/or an endogenous substrate, (3) a method for screening a substance capable of expressing cytotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (4) a method for screening a substance capable of expressing genotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (5) a method for screening a substance capable of expressing carcinogenicity by the metabolism of a xenobiotic and/or an endogenous substrate, (6) a method for screening a substance capable of expressing mutagenicity by the metabolism of a xenobiotic and/or an endogenous substrate, (7) a method for screening a substance capable of expressing hepatotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (8) a method for screening a xenobiotic and/or an endogenous substrate which acts on the liver, and (9) a method for screening a substance capable of acquiring a new physiological activity or increasing or decreasing the inherent physiological activity, through the metabolism of a xenobiotic and/or an endogenous substrate, each method comprising use of the cell line according to 1.

4. A compound or its salt obtainable using the screening method according to 3.

#### BACKGROUND ART

Hepatocytes are known to have a great many physiological functions and of all those, play a very important function in terms of the metabolism of xenobiotics and/or endogenous substrates such as drugs, food additives, environmental pollutants, industrial chemicals and the like. At the same time, the function of metabolizing xenobiotics and/or endogenous substrates

might lead to induce the inhibition of metabolizing enzymes for xenobiotics and/or endogenous substrates by xenobiotics and/or endogenous substrates, to accelerate the activity of metabolizing enzymes for xenobiotics and/or endogenous substrates, to express cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates, to express genotoxicity by the metabolism of xenobiotics and/or endogenous substrates, to express carcinogenicity by the metabolism of xenobiotics and/or endogenous substrates, to express mutagenicity by the metabolism of xenobiotics and/or endogenous substrates, to express hepatotoxicity by the metabolism of xenobiotics and/or endogenous substrates, and so on. For these reasons, the function of xenobiotics and/or endogenous substrates has been widely studied. It is known that many enzymes are associated with the metabolism of xenobiotics and/or endogenous substrates referred to herein. Examples of such enzymes include UDP-glucuronosyltransferase, sulfotransferase, glutathione transferase, epoxy hydratase, N-acetyltransferase, flavin monooxygenase and cytochromes P450. And, the presence of a cytochrome P450 reductase is crucial to express the enzymatic function of cytochromes P450. Of an array of these enzymes, cytochromes P450 play the most important role in the metabolism of xenobiotics and/or endogenous substrates. The term cytochromes P450 collectively refers to a class of enzymes including a great many molecular species. In the metabolism of xenobiotics and/or endogenous substrates in human liver, ten (10) species of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 are considered important. Also, these enzymes distributed in human liver are functionally different depending on species and hence, human-derived liver specimens are unable to use as a stable test system. On the other hand, such a metabolic function of the liver involves a very strong specificity, i.e.,

10009158-102504  
T05207-85T60001

10009158 102501

5 differences in nature, depending on species, which makes  
it difficult to predict such diverse metabolic functions  
of human liver from experimental animals, e.g., rats.  
However, it is practically impossible to analyze these  
10 items of interest in human. For these reasons, human-  
derived cultured hepatocytes are considered useful not only  
in examining the function of human liver in a rapid,  
inexpensive, safe and accurate way provide in place of  
experimental animals, but also in producing so-called  
artificial liver as a substitute for human liver in function.  
15 However, it is impossible to subculture human normal  
hepatocytes separated from tissues in vivo. Cells that can  
be established into a cell line often lack the  
differentiation capability possessed inherently and in  
most cases, do not exactly reflect the function of tissues  
20 to which the cell line originally belongs. A family of  
enzymes that metabolize xenobiotics and/or endogenous  
substrates especially in liver cells, among others, the  
family of cytochromes P450 molecular species loses its  
activity in an extremely short period of time in primary  
25 culture; any cell line that fully retains the property has  
not been found so far (J. Dich et al., Hepatology, 8, 39-45  
(1988)). Thus, in light of the foregoing, there is an  
extensive need for hepatocytes that can retain the  
30 capability of metabolizing xenobiotics and/or endogenous  
substrates and can be incubated.

30 To date, however, no cultured cell line has been  
obtained as retaining the function associated with the  
metabolism of xenobiotics and/or endogenous substrates as  
in the liver. Particularly because the activity of  
cytochromes P450 is widely recognized to be rapidly lost  
in cultured cells, it has been hitherto attempted to stably  
express cytochromes P450 in the established cultured cells  
and by this, take over the metabolizing function of liver  
35 (M. Sawada et al., Mutation Research, 411, 19-43 (1998)).

However, as stated above, the cell line to express cytochromes P450 should indispensably be derived from human liver cells. In addition, the activity of NADPH cytochromes P450 reductase is required for expressing the activity of cytochromes P450, requiring further expression of many more enzymes. Therefore, stable and safe reproduction of the metabolizing function in human liver should be in human-derived cultured hepatocytes that retain the activity of enzymes participating in the metabolism of cytochromes P450 as well as various other metabolisms.

As examples of the expression of cytochromes P450 in cells retaining the activity of various enzymes participating in metabolism, there are cases in which P450 was expressed in HepG2 cells using vaccinia virus (Methods in Enzymology, T. Aoyama et al. in Methods in Enzymology, 260, 85-92, edited by M. R. Waterman, Academic Press, 1991) and in which CYP2E1 was expressed in HepG2 cells (Y. Dai et al., Biochemistry, 32, 6928-6937, 1993). In the former case, careful handling is required, which is an obstacle to practical application. The latter was attempted for CYP2E1 alone but so far none has been attempted for many other species of cytochromes P450 present in the liver. Accordingly, if a cultured cell line that can retain the activity of a family of enzymes participating in the metabolism of xenobiotics and/or endogenous substrates in the liver could be obtained, this will enable to (1) analyze an enzyme participating in the metabolism of xenobiotics and/or endogenous substrates, (2) analyze a metabolic pathway of xenobiotics and/or endogenous substrates, (3) analyze a chemical structure of the metabolite of xenobiotics and/or endogenous substrates, (4) prepare the metabolite of xenobiotics and/or endogenous substrates, (5) analyze inhibition of the metabolizing enzyme for xenobiotics and/or endogenous substrates, (6) analyze an accelerated activity of the metabolizing enzyme for

10009158-102501

Small Port  
Vacc.

Sul  
A<sup>5</sup>

Sul  
A<sup>3</sup>

10009150-102501  
Suf 3

xenobiotics and/or endogenous substrates, (7) analyze  
expression of cytotoxicity by the metabolism of xenobiotics  
and/or endogenous substrates, (8) analyze expression of  
genotoxicity by the metabolism of xenobiotics and/or  
5 endogenous substrates, (9) analyze expression of  
carcinogenicity by the metabolism of xenobiotics and/or  
endogenous substrates, (10) analyze mutagenicity by the  
metabolism of xenobiotics and/or endogenous substrates,  
(11) analyze expression of hepatotoxicity by the metabolism  
10 of xenobiotics and/or endogenous substrates, and (12)  
analyze xenobiotics and/or endogenous substrates that act  
on the liver; furthermore, such will enable to (1) screen  
a substance capable of inhibiting xenobiotics and/or  
endogenous substrates, (2) screen a substance capable of  
15 accelerating the activity of metabolizing enzymes for  
xenobiotics and/or endogenous substrates, (3) screen a  
substance capable of expressing cytotoxicity by the  
metabolism of xenobiotics and/or endogenous substrates,  
(4) screen a substance capable of expressing genotoxicity  
20 by the metabolism of xenobiotics and/or endogenous  
substrates, (5) screen a substance capable of expressing  
carcinogenicity by the metabolism of xenobiotics and/or  
endogenous substrates, (6) screen a substance capable of  
expressing mutagenicity by the metabolism of xenobiotics  
25 and/or endogenous substrates, (7) screen a substance  
capable of expressing hepatotoxicity by the metabolism of  
xenobiotics and/or endogenous substrates, (8) screen  
xenobiotics and/or endogenous substrates which act on the  
liver, and (9) screen a substance capable of acquiring a  
30 new physiological activity or increasing or decreasing the  
inherent physiological activity, through the metabolism of  
xenobiotics and/or endogenous substrates. Thus, specific  
compounds or salts thereof, etc. can be obtained using the  
method for analysis and/or the method for screening above.

## DISCLOSURE OF THE INVENTION

An object of this invention is to provide a cultured cell line derived from human liver, thereby to separate and produce the cell line that can stably express human cytochromes P450 CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.

These cells enable to (1) analyze an enzyme participating in the metabolism of xenobiotics and/or endogenous substrates, (2) analyze a metabolic pathway of xenobiotics and/or endogenous substrates, (3) analyze a chemical structure of the metabolite of xenobiotics and/or endogenous substrates, (4) prepare the metabolite of xenobiotics and/or endogenous substrates, (5) analyze inhibition of the metabolizing enzyme for xenobiotics and/or endogenous substrates, (6) analyze an accelerated activity of the metabolizing enzyme for xenobiotics and/or endogenous substrates, (7) analyze expression of cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (8) analyze expression of genotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (9) analyze expression of carcinogenicity by the metabolism of xenobiotics and/or endogenous substrates, (10) analyze mutagenicity by the metabolism of xenobiotics and/or endogenous substrates, (11) analyze the expression of hepatotoxicity by the metabolism of xenobiotics and/or endogenous substrates, and (12) analyze xenobiotics and/or endogenous substrates that act on the liver. The cells further enable to (1) screen a substance capable of inhibiting xenobiotics and/or endogenous substrates, (2) screen a substance capable of accelerating the activity of metabolizing enzymes for xenobiotics and/or endogenous substrates, (3) screen a substance capable of expressing cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates,

10009158.102501

Sub  
A4

10000150102501  
 Sub A4

(4) screen a substance capable of expressing genotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (5) screen a substance capable of expressing carcinogenicity by the metabolism of xenobiotics and/or endogenous substrates, (6) screen a substance capable of expressing mutagenicity by the metabolism of xenobiotics and/or endogenous substrates, (7) screen a substance capable of expressing hepatotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (8) screen xenobiotics and/or endogenous substrates which act on the liver, and (9) screen a substance capable of acquiring a new physiological activity or increasing or decreasing the inherent physiological activity, through the metabolism of xenobiotics and/or endogenous substrates. Thus, particular compounds or salts thereof, etc. can be obtained, using the method for analysis and/or the method for screening.

Sub A5

In view of the foregoing problems, the present inventors have made extensive studies and as a result, have established stable transformants capable of stably expressing cytochromes P450 in a human hepatic carcinoma-derived cell line with an enhanced activity that participate in the metabolism of xenobiotics and/or endogenous substrates. The following further studies have resulted in accomplishing this invention.

That is, the present invention relates to the following features.

(1) A cell line derived from human hepatic carcinoma capable of stably expressing human cytochromes P450.

(2) The cell line according to (1), wherein human cytochromes P450 are capable of stably expressing CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.

(3) The cultured cell line according to (1), wherein the human hepatic carcinoma cell is HepG2.

(4) The cell line according to (1), which is Hepc/1A1.4, Hepc/1A2.9, Hepc/2B6.68, Hepc/2C8.46, Hepc/2C9.1, Hepc/2C19.12, Hepc/2D6.39, Hepc/2E1.3-8 or Hepc/3A4.5.

5 (5) A method for analyzing (a) an enzyme participating in the metabolism of a xenobiotic and/or an endogenous substrate, (b) a metabolic pathway of a xenobiotic and/or an endogenous substrate, (c) a chemical structure of the metabolite of a xenobiotic and/or an endogenous substrate, (d) inhibition of the metabolizing enzyme for a xenobiotic  
10 and/or an endogenous substrate, (e) an accelerated activity of the metabolizing enzyme for a xenobiotic and/or an endogenous substrate, (f) cytotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (g) genotoxicity by the metabolism of a xenobiotic and/or an  
15 endogenous substrate, (h) carcinogenicity by the metabolism of a xenobiotic and/or endogenous substrate, (i) mutagenicity by the metabolism of a xenobiotic and/or an endogenous substrate, (j) hepatotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, or (k) a  
20 xenobiotic and/or an endogenous substrate that acts on the liver.

(6) A method for preparing the metabolite of a xenobiotic and/or an endogenous substrate, which comprises using the cell line according to (1).

25 (7) A method for screening a substance which comprises using the cell line according to (1), wherein the substance is (a) a substance capable of inhibiting a xenobiotic and/or an endogenous substrate, (b) a substance capable of accelerating an activity of the metabolizing enzyme for a  
30 xenobiotic and/or an endogenous substrate, (c) a substance capable of expressing cytotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (d) a substance capable of expressing genotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (e) a substance  
35 capable of expressing carcinogenicity by the metabolism of

10009158-10501

a xenobiotic and/or an endogenous substrate, (f) a substance capable of expressing mutagenicity by the metabolism of a xenobiotic and/or an endogenous substrate, (g) a substance capable of expressing hepatotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (h) a xenobiotic and/or an endogenous substrate which acts on the liver, or (i) a substance capable of acquiring a new physiological activity or increasing or decreasing the inherent physiological activity, through the metabolism of a xenobiotic and/or an endogenous substrate.

(8) A compound or its salt which is obtainable using the method according to (7).

(9) A pharmaceutical composition comprising the compound or its salt according to (8).

(10) A method for analysis which comprises using at least two cultured cell lines derived from human liver capable of stably expressing at least one of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, said analysis being for (a) an enzyme that participates in the metabolism of a xenobiotic and/or an endogenous substrate, (b) a metabolic pathway of a xenobiotic and/or an endogenous substrate, (c) a chemical structure of the metabolite of a xenobiotic and/or an endogenous substrate, (d) inhibition of the metabolizing enzyme for a xenobiotic and/or an endogenous substrate, (e) an accelerated activity of the metabolizing enzyme for a xenobiotic and/or an endogenous substrate, (f) cytotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (g) genotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (h) carcinogenicity by the metabolism of a xenobiotic and/or endogenous substrate, (i) mutagenicity by the metabolism of a xenobiotic and/or an endogenous substrate, (j) hepatotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, or (k) a xenobiotic and/or an

endogenous substrate that acts on the liver.

(11) A method for preparation of the metabolite of a xenobiotic and/or an endogenous substrate, which comprises using at least two cultured cell lines from human liver capable of stably expressing at least one of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.

(12) A method for screening a substance which comprises using at least two cultured cell lines from human liver capable of stably expressing at least one of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, said substance being (a) a substance capable of inhibiting the metabolizing enzyme for a xenobiotic and/or an endogenous substrate, (b) a substance capable of accelerating an activity of the metabolizing enzyme for a xenobiotic and/or an endogenous substrate, (c) a substance capable of expressing cytotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (d) a substance capable of expressing genotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (e) a substance capable of expressing carcinogenicity by the metabolism of a xenobiotic and/or an endogenous substrate, (f) a substance capable of expressing mutagenicity by the metabolism of a xenobiotic and/or an endogenous substrate, (g) a substance capable of expressing hepatotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (h) a xenobiotic and/or an endogenous substrate which acts on the liver, or (i) a substance capable of acquiring a new physiological activity or increasing or decreasing the inherent physiological activity, through the metabolism of a xenobiotic and/or an endogenous substrate.

(13) A compound or a salt thereof, which is obtainable using the method according to (12).

(14) A pharmaceutical compound comprising a compound or a salt thereof according to (13).

10005158-103504  
T05207-8515007

## BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the results by the MTT assay method relating to expression of cytotoxicity of acetaminophen shown in EXAMPLE 4, wherein symbols -- , -- , -- and - denote HepG2, Hepc/2E1.3-8, HepG2 + 100  $\mu$ M BSO and Hepc/2E1.3-8 + 100  $\mu$ M BSO, respectively.

FIG. 2 shows the results by the LDH leakage test on expression of cytotoxicity of acetaminophen shown in EXAMPLE 4, wherein symbols -- , -- , -- and -- denote HepG2, Hepc/2E1.3-8, HepG2 + 100  $\mu$ M BSO and Hepc/2E1.3-8 + 100  $\mu$ M BSO, respectively.

FIG. 3 shows the results by the MTT assay method relating to expression of cytotoxicity of benzanthrane shown in EXAMPLE 5, wherein symbols -- and -- denote HepG2 and Hepc/1A1.4, respectively.

FIG. 4 shows the results by the MTT assay method relating to expression of cytotoxicity of cyclophosphamide shown in EXAMPLE 6, wherein symbols -- and -- denote HepG2 and Hepc/2B6.68, respectively.

FIG. 5 shows the results by the LDH leakage test on expression of cytotoxicity of cyclophosphamide shown in EXAMPLE 6, wherein symbols -- and -- denote HepG2 and Hepc/2B6.68, respectively.

FIG. 6 shows the results of the test on inhibition of ketoconazole against the CYP3A4 activity shown in EXAMPLE 7, wherein symbol - - denotes ketoconazole.

FIG. 7 shows the results of the test on the CYP2E1 activity induction shown in EXAMPLE 8.

## BEST MODE OF EMBODIMENT OF THE INVENTION

Throughout the specification, the term "xenobiotics or foreign matters in vivo" collectively refers to, e.g.,  
35 medicaments, food additives, environmental pollutants,

chemicals in general, etc. and the term "endogenous substrates" refers to all substances present in vivo. For the metabolism of xenobiotics, among others, medicaments or drugs as the main component, drug metabolism is preferably used.

The human hepatic carcinoma cells used can be collected by separating a human hepatic carcinoma-derived cultured cell line (preferably HepG2) from human hepatic carcinoma. Genes that encode various species of cytochromes P450 separately separated are stably expressed in the human hepatic carcinoma cells.

In order to stably express DNA fragments encoding cytochromes P450, first, DNA fragments encoding, e.g., individual cytochromes P450 are obtained and placed under control of a foreign promoter for expression. The base sequences of DNA fragments encoding cytochromes P450 are available from public database. Based on the base sequences, cytochromes P450-encoding DNA fragment can be separated by publicly known methods including PCR, hybridization screening, etc. The DNA fragment thus obtained is inserted into a vector which produces transformants capable of stably expressing a foreign gene in a mammal cultured cell, whereby a vector for transformation is produced. The resulting vector is transfected to hepatic carcinoma cells by publicly known methods. Transformants are selected by examining the enzyme activity induced by the expression of cytochromes P450 transformed therein, thereby to select excellent clones. In addition, clones obtained can be confirmed with stability of their property, by repeating freezing storage.

Examples of the foreign promoter include SR $\alpha$  promoter, SV40 promoter, LTR promoter, CMV promoter and HSV-TK promoter.

The term "stably expressing human cytochromes P450" is used to mean that the expression of human cytochromes

P450 is not transient and specifically, the activity of  
 cytochromes P450 is not lost when cells are cultured  
 (subcultured). The cells capable of expressing human  
 cytochromes P450 are preferably cells in which not only  
 cytochromes P450 but also enzymes associated with various  
 metabolisms (specifically, UDP-glucuronosyltransferase,  
 sulfotransferase, glutathione transferase, epoxy  
 hydratase, N-acetyltransferase, flavin monooxygenase,  
 etc.) are capable of functioning.

Examples of the cytochromes P450 molecular species  
 which participate in the metabolism of xenobiotics and/or  
 endogenous substrates in liver include CYP1A1, CYP1A2,  
 CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and  
 CYP3A4. These enzymes not only catalyze the metabolism of  
 xenobiotics and/or endogenous substrates but also induce,  
 depending upon properties of their metabolites, the  
 inhibition of metabolizing enzymes for xenobiotics and/or  
 endogenous substrates, the acceleration of the activity of  
 metabolizing enzymes for xenobiotics and/or endogenous  
 substrates, the expression of cytotoxicity by the  
 metabolism of xenobiotics and/or endogenous substrates,  
 the expression of genotoxicity by the metabolism of  
 xenobiotics and/or endogenous substrates, the expression  
 of carcinogenicity by the metabolism of xenobiotics and/or  
 endogenous substrates, the expression of mutagenicity by  
 the metabolism of xenobiotics and/or endogenous substrates,  
 the expression of hepatotoxicity by the metabolism of  
 xenobiotics and/or endogenous substrates, and so on.  
 However, these functions associated with the metabolism of  
 xenobiotics and/or endogenous substrates are not only  
 catalyzed by cytochromes P450 alone but are dependent on  
 concerted actions with various enzymes such as UDP-  
 glucuronosyltransferase, sulfotransferase, glutathione  
 transferase, epoxy hydratase, N-acetyltransferase, flavin  
 monooxygenase and cytochromes P450 reductase.

T0500T" 85T6000T

Sub  
A8

For reproducing the function of the liver by expressing cytochromes P450, the cells should thus be those capable of functioning at least, human-derived UDP-glucuronosyltransferase, sulfotransferase, glutathione transferase, epoxy hydratase, N-acetyltransferase or flavin monooxygenase in the cells. One of such cells is cultured cell HepG2 originating from human hepatic carcinoma. The HepG2 cell is known to be capable of functioning UDP-glucuronosyltransferase, sulfotransferase, glutathione transferase, epoxy hydratase, N-acetyltransferase, flavin monooxygenase and NADPH P450 reductase function in HepG2 (J. Rueff et al., Mutation Research, 353, 151-176 (1996)). In light of the foregoing, the present inventors have succeeded in stably expressing cytochromes P450 in HepG2 thereby to reproduce the function of human liver in a rapid, inexpensive, safe and accurate fashion.

In particular, preferably used are Hepc/3A4.5, Hepc/2E1.3-8, Hepc/2C9.1, Hepc/2C8.46, Hepc/1A2.9, Hepc/1A1.4, Hepc/2B6.68, Hepc/2D6.39, Hepc/2A6L.9, Hepc/2C19.12, etc.

Hepc/3A4.5, Hepc/2E1.3-8, Hepc/2C9.1, Hepc/2C8.46, Hepc/1A2.9, Hepc/1A1.4, Hepc/2B6.68, Hepc/2D6.39, Hepc/2A6L.9 and Hepc/2C19.12 are highly active cells obtained by the expression of CYP3A4, CYP2E1, CYP2C9, CYP2C8, CYP1A2, CYP1A1, CYP2B6, CYP2D6, CYP2A6 and CYP2C19, respectively.

The present invention further relates to a method, which comprises using the aforesaid human hepatic carcinoma-derived cultured cell line capable of stably expressing human cytochromes P450, including (a) a method for analyzing an enzyme participating in the metabolism of a xenobiotic and/or an endogenous substrate, (b) a method for analyzing a metabolic pathway of a xenobiotic and/or an endogenous substrate, (c) a method for analyzing a

FOG200T 85T500T

Sub  
A<sup>9</sup>

Sub  
A<sup>10</sup><sub>20</sub>

chemical structure of the metabolite of a xenobiotic and/or an endogenous substrate, (d) a method for preparing the metabolite of a xenobiotic and/or an endogenous substrate, (e) a method for analyzing inhibition of the metabolizing enzyme for a xenobiotic and/or an endogenous substrate, (f) a method for analyzing an accelerated activity of the metabolizing enzyme for a xenobiotic and/or an endogenous substrate, (g) a method for analyzing expression of cytotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (h) a method for analyzing expression of genotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, (i) a method for analyzing expression of carcinogenicity by the metabolism of a xenobiotic and/or endogenous substrate, (j) a method for analyzing mutagenicity by the metabolism of a xenobiotic and/or an endogenous substrate, (k) a method for analyzing expression of hepatotoxicity by the metabolism of a xenobiotic and/or an endogenous substrate, and (l) a method for analyzing a xenobiotic and/or an endogenous substrate that acts on the liver.

The respective methods described in (a) through (l) are described below.

(a) Method for analyzing an enzyme participating in the metabolism of xenobiotics and/or endogenous substrates:

By analyzing a change in the structure of xenobiotics and/or endogenous substrates through exposure of a test specimen, e.g., to the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes P450, enzymes that participate in the metabolism of xenobiotics and/or endogenous substrates can be analyzed (J. L. Napoli et al., Methods in Enzymology, vol. 206, pp. 491-501, Ed. by M. R. Waterman et al., Academic Press, 1991; H. K. Kroemer et al., Methods in Enzymology, vol. 272, pp. 99-108, Ed. by M. R. Waterman et al., Academic Press, 1996). Specific examples include identification of an enzyme

FOUO 85150001

Cyfl  
A

participating the metabolism of xenobiotics and/or endogenous substrates by analyzing a change in the structure of xenobiotics and/or endogenous substrates upon exposure of a test specimen to the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes P450, analysis of the mechanism in an enzymatic reaction by analyzing a change in the structure of xenobiotics and/or endogenous substrates upon exposure of a test specimen of interest to the cell, and analysis of substrate specificity.

Examples of the test specimen to be tested include a peptide, a protein, a non-peptidic compound, a synthetic compound, a fermentation product, a cell extract, a plant extract, an animal tissue extract, plasma, etc. These substances may be either novel or publicly known ones.

(b) Method for analyzing a metabolic pathway of xenobiotics and/or endogenous substrates:

By analyzing a change in the structure of xenobiotics and/or endogenous substrates through exposure of a test specimen, e.g., to the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes P450, the metabolic pathway of xenobiotics and/or endogenous substrates can be analyzed (J. L. Napoli et al., Methods in Enzymology, vol. 206, pp. 491-501, Ed. by M. R. Waterman et al., Academic Press, 1991; H. K. Kroemer et al., Methods in Enzymology, vol. 272, pp. 99-108, Ed. by M. R. Waterman et al., Academic Press, 1996).

The examples of the test specimen given above apply also to the specimen to be tested here.

(c) Method for analyzing a chemical structure of the metabolite of xenobiotics and/or endogenous substrates:

By analyzing a change in the structure of xenobiotics and/or endogenous substrates caused upon exposure of a test specimen, e.g., to the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes

10009158-102501

Sub  
A11

P450, the chemical structure of the metabolite of xenobiotics and/or endogenous substrates can be analyzed (J. L. Napoli et al., Methods in Enzymology, vol. 206, pp. 491-501, Ed. by M. R. Waterman et al., Academic Press, 1991; 5 H. K. Kroemer et al., Methods in Enzymology, vol. 272, pp. 99-108, Ed. by M. R. Waterman et al., Academic Press, 1996).

The examples of the test specimen given above apply also to the specimen to be tested here.

(d) Method for preparing the metabolite of xenobiotics and/or endogenous substrates:

Sub A12  
By collecting the altered product (so called metabolite) from xenobiotics and/or endogenous substrates produced as a result of exposing a test specimen, e.g., to the human hepatic carcinoma-derived cultured cell line 15 capable of stably expressing cytochromes P450 and purifying and separating the product in an appropriate manner, the metabolite of xenobiotics and/or endogenous substrates can be prepared (J. L. Napoli et al., Methods in Enzymology, vol. 206, pp. 491-501, Ed. by M. R. Waterman et al., Academic 20 Press, 1991).

The examples of the test specimen given above apply also to the specimen to be tested here.

(e) Method for analyzing inhibition of the metabolizing enzyme for xenobiotics and/or endogenous substrates:

Sub AB  
By exposing a test specimen, e.g., to the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes P450, the inhibition of a metabolizing enzyme for xenobiotics and/or endogenous substrates can be analyzed (J. L. Napoli et al., Methods 30 in Enzymology, vol. 206, pp. 491-501, Ed. by M. R. Waterman et al., Academic Press, 1991). Specifically, the inhibition can be detected by the inhibition of cytochromes P450 enzyme activity, reduction in the amount of protein, decreased mRNA, etc. The detection may be made using publicly known 35 methods, including assay for enzyme activity corresponding

10009158-102504

to the respective members of P450, western blotting corresponding to the respective P450 proteins, northern hybridization corresponding to various P450 mRNAs, RT-PCR, etc.

(f) Method for analyzing an accelerated activity of the metabolizing enzyme for xenobiotics and/or endogenous substrates:

10 By exposing a test specimen, e.g., to the human hepatic  
carcinoma-derived cultured cell line capable of stably  
expressing cytochromes P450 and detecting the increased  
enzyme activity in the metabolism of xenobiotics and/or  
endogenous substrates, the increased amount of the enzyme  
15 or the increased amount of transcription in gene encoding  
the enzyme, the accelerated activity of the metabolizing  
enzyme for xenobiotics and/or endogenous substrates can be  
analyzed (J. Rueff et al., Mutation Research, 353 (1996)  
151-176). Specifically, the accelerated activity can be  
20 analyzed by detecting the increased enzyme activity of  
cytochromes P450, the increased amount of protein or the  
increased mRNA. The detection may be made using publicly  
known methods, including western blotting corresponding to  
the respective P450 proteins, northern hybridization  
25 corresponding to various P450 mRNAs, RT-PCR, etc.

(g) Method for analyzing cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates:

30 By exposing a test specimen, e.g., to the human hepatic  
carcinoma-derived cultured cell line capable of stably  
expressing cytochromes P450, the cytotoxicity caused by the  
metabolism of xenobiotics and/or endogenous substrates can  
be analyzed. Specifically, the cytotoxicity can be analyzed  
35 by observing a morphological change of the cell caused upon

Sub AD

5

10

(h) Method for analyzing expression of genotoxicity by the metabolism of xenobiotics and/or endogenous substrates:

Sub  
A16

15

30

(i) Method for analyzing carcinogenicity by the metabolism of a xenobiotic and/or endogenous substrate:

Suh  
K17 35

35

Sub  
A17

15 (j) Method for analyzing mutagenicity by the metabolism of xenobiotics and/or endogenous substrates:

35

35  
Sub  
A/c

## The hepatotoxicity by the metabolism of xenobiotics

and/or endogenous substrates can be analyzed either by exposing a test specimen, e.g., to the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes P450 and then observing the expression of cytotoxicity, or by exposing a test specimen to the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes P450, administering the test specimen altered by the cells to other liver cells, liver slices or removed liver or to experimental animal and then observing a change in cell or tissue or an in vivo change caused thereby.

The examples of the test specimen given above apply also to the specimen to be tested here.

(1) Method for analyzing xenobiotics and/or endogenous substrates that act on the liver:

The expression of the action on the liver can be analyzed either by exposing a test specimen, e.g., to the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes P450 and then observing the expression of a change in the cells caused, or by exposing a test specimen to the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes P450, administering the test specimen altered by the cells to other liver cells, liver slices or removed liver or to experimental animal and then observing a change in cell or tissue or an in vivo change caused thereby.

The examples of the test specimen given above apply also to the specimen to be tested here.

Furthermore, the present invention provides a method for screening a substance, which comprises using the human hepatic carcinoma-derived cultured cell line capable of stably expressing cytochromes P450, as well as a compound or its salt obtainable by the screening method, wherein the substance to be screened is (A) a substance capable of

10009150-102501

Sub  
A18

10009150-10507  
inhibiting the metabolizing enzyme for xenobiotics and/or  
endogenous substrates, (B) a substance capable of  
accelerating an activity of the metabolizing enzyme for  
xenobiotics and/or endogenous substrates, (C) a substance  
5 capable of expressing cytotoxicity by the metabolism of  
xenobiotics and/or endogenous substrates, (D) a substance  
capable of expressing genotoxicity by the metabolism of  
xenobiotics and/or endogenous substrates, (E) a substance  
capable of expressing carcinogenicity by the metabolism of  
10 xenobiotics and/or endogenous substrates, (F) a substance  
capable of expressing mutagenicity by the metabolism of  
xenobiotics and/or endogenous substrates, (G) a substance  
capable of expressing hepatotoxicity by the metabolism of  
xenobiotics and/or endogenous substrates, (H) xenobiotics  
15 and/or endogenous substrates which act on the liver, or (I)  
a substance capable of acquiring a new physiological  
activity or increasing or decreasing the inherent  
physiological activity, through the metabolism of  
xenobiotics and/or endogenous substrates.

20 (A) According to the method for screening a substance  
capable of inhibiting the metabolizing enzyme for  
xenobiotics and/or endogenous substrates, the inhibition  
is analyzed by the method described in (e) above for  
analyzing the inhibition of a metabolizing enzyme for  
25 xenobiotics and/or endogenous substrates, in which such a  
substance that inhibits the enzyme activity of cytochromes  
P450, reduces the amount of protein or reduces mRNA can be  
selected as the substance capable of inhibiting the enzyme  
activity for xenobiotics and/or endogenous substrates.

30 (B) According to the method for screening a substance  
capable of accelerating an activity of the metabolizing  
enzyme for xenobiotics and/or endogenous substrates, the  
acceleration is analyzed by the method described in (f)  
above for analyzing the acceleration of a metabolizing  
35 enzyme for xenobiotics and/or endogenous substrates, in

which such a substance that accelerates the enzyme activity of cytochromes P450, increases the amount of protein or increases mRNA can be selected as the substance capable of inhibiting the enzyme activity for xenobiotics and/or endogenous substrates.

(C) According to the method for screening a substance capable of expressing cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates, the cytotoxicity is analyzed by the method described in (g) above for analyzing the cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates, in which such a substance that causes, e.g., a morphological change of the cell upon exposure of a test specimen, a change in viable cell count, leakage of intracellular enzyme, a change in structure of cells in the top layer, a change in intracellular enzyme, etc. can be selected as the substance capable of expressing the cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates.

(D) According to the method for screening a substance capable of expressing genotoxicity by the metabolism of xenobiotics and/or endogenous substrates, the genotoxicity can be analyzed by the method described in (h) above for analyzing the genotoxicity by the metabolism of xenobiotics and/or endogenous substrates, in which such a test specimen that causes genotoxicity through the metabolism of xenobiotics and/or endogenous substrates by subjecting to, e.g., the chromosomal aberration test or the micronucleus test can be selected as a substance capable of expressing the genotoxicity by the metabolism of xenobiotics and/or endogenous substrates.

(E) According to the method for screening a substance capable of expressing carcinogenicity by the metabolism of xenobiotics and/or endogenous substrates, the carcinogenicity can be analyzed by the method described in (i) above for analyzing the carcinogenicity by the

10009458-102504

metabolism of xenobiotics and/or endogenous substrates, in which such a test specimen that causes carcinogenicity through the metabolism of xenobiotics and/or endogenous substrates by subjecting to, e.g., the chromosomal aberration test or the DNA modification can be selected as a substance capable of expressing the carcinogenicity by the metabolism of xenobiotics and/or endogenous substrates.

(F) According to the method for screening a substance capable of expressing mutagenicity by the metabolism of xenobiotics and/or endogenous substrates, the mutagenicity can be analyzed by the method described in (j) above for analyzing the mutagenicity by the metabolism of xenobiotics and/or endogenous substrates, in which such a test specimen that causes mutagenicity through the metabolism of xenobiotics and/or endogenous substrates by subjecting to, e.g., the chromosomal aberration test or the micronucleus test can be selected as a substance capable of expressing the mutagenicity by the metabolism of xenobiotics and/or endogenous substrates.

(G) According to the method for screening a substance capable of expressing hepatotoxicity by the metabolism of xenobiotics and/or endogenous substrates, the hepatotoxicity can be analyzed following the method described in (k) above for analyzing the hepatotoxicity by the metabolism of xenobiotics and/or endogenous substrates, which involves, e.g., exposing a test specimen to cells, administering the test specimen altered by the cells to other liver cells, liver slices, removed liver or experimental animal, and observing a change in cells or tissues or a change in vivo. Such a test specimen that causes hepatotoxicity through the metabolism of xenobiotics and/or endogenous substrates can be selected as a substance capable of expressing the hepatotoxicity by the metabolism of xenobiotics and/or endogenous

substrates.

(H) According to the method for screening xenobiotics and/or endogenous substrates which act on the liver, substances are analyzed by the method described in (1) above for analyzing xenobiotics and/or endogenous substrates which act on the liver, which involves, e.g., exposing a test specimen to a cell, administering the test specimen altered by the cell to other liver cells, liver slices, removed liver or experimental animal and then observing a change in cells or tissue or a change in vivo thereby. Thus, the xenobiotics and/or endogenous substrates which act on the liver can be screened.

(I) According to the method for screening a substance capable of acquiring a new physiological activity or increasing or decreasing the inherent physiological activity (including a so-called prodrug) through the metabolism of xenobiotics and/or endogenous substrates, the screening can be effected following the method described in (c) above for analyzing the chemical structure of the metabolite of xenobiotics and/or endogenous substrates and observing the physiological activity of the metabolite.

The compound or its salt that is obtainable by the screening methods described in (A) through (I) above is the compound or its salt selected from the test specimens that cause the activities, properties, etc. described above. Since these compounds are effective for the treatment and prevention of diseases (e.g., hepatic dysfunction) associated with metabolic aberration of xenobiotics in the liver, these compounds may be used as safe and low toxic pharmaceutical composition for the treatment and prevention of such diseases.

The compounds obtained by the screening methods above may be in the form of salts. As such salts of the compounds, there are salts with physiologically acceptable acids (e.g.,

40009453 102504

10009150-102501  
inorganic acids or organic acids) or bases (e.g., alkaline metals), with physiologically acceptable acid additions salts being particularly preferred. Examples of such salts include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid) and salts  
5 with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic  
10 acid).

Pharmaceutical compositions comprising the compounds or salts thereof obtained by the screening methods may be manufactured by publicly known methods or those similar thereto. Since the pharmaceutical compositions thus  
15 obtained are safe and low toxic, the compositions can be administered, e.g., to human or another mammal (e.g., rat, mouse, guinea pig, rabbit, sheep, swine, bovine, horse, cat, dog, monkey, etc.).

The dose of the compound or its salts may vary depending on target disease, subject to be administered, routes for  
20 administration, etc.; for the purpose of treating, e.g., hepatic dysfunction by oral administration of the compound, the dose is normally about 0.1 to about 100 mg, preferably about 1.0 to about 50 mg, more preferably about 1.0 to about  
25 20 mg per day for adult (as 60 kg body weight). In parenteral administration, the single dose varies depending on subject to be administered, target disease, etc.; when administered in the form of an injection for the purpose of treating, e.g., hepatic dysfunction, it is advantageous to administer  
30 the compound intravenously at a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, more preferably about 0.1 to about 10 mg for adult (as 60 kg body weight). For other animal species, the corresponding dose as converted per 60 kg weight can be administered.

35 Specific examples of pharmaceutical preparations

available for the form given above include tablets  
(including sugar coated tablets and film coated tablets),  
pills, capsules (including microcapsules), granules, fine  
granules, powders, syrup, emulsion, suspension,  
5 injections, inhalation, ointments, etc. These  
pharmaceutical preparations are prepared in a conventional  
manner (e.g., following the methods described in the  
Japanese Pharmacopoeia).

10 In the pharmaceutical preparation above, the amount  
of the compound or its salt obtained by the screening  
methods above may vary depending on the form of preparation  
but in general, is within a range of 0.01 to 100 wt%,  
preferably 0.1 to 50 wt%, more preferably 0.5 to 20 wt%,  
based on the total weight of the pharmaceutical  
15 preparation.

Specifically, tablets may be manufactured by  
subjecting drugs directly to compression molding, or by  
adding to the drugs an excipient, a binder, a disintegrator  
or other suitable additives, uniformly blending the  
20 resulting mixture, grinding to granules, adding a lubricant  
to the granules and then subjecting to compression molding.  
Alternatively, drugs may be subjected directly to  
compression molding; or an excipient, a binder, a  
disintegrator or other suitable additives are added to the  
25 drugs, uniformly blended and finally compression-molded.  
The pharmaceutical preparation may also be prepared by  
subjecting granules previously made directly to  
compression molding or after adding suitable additives to  
the granules and uniformly blending them. The  
30 pharmaceutical preparation may also be added with, if  
desired, a coloring agent, a corrigent, etc. Furthermore,  
the pharmaceutical preparation may also be coated with an  
appropriate coating agent.

To prepare injection, a predetermined amount of the  
35 medicament is dissolved, suspended or emulsified in water

100009150-102501  
T05201-0510001

for injection, physiological saline, Ringer's fluid, etc.,  
 or usually in vegetable oil when using a non-aqueous solvent.  
 Thus, the medicament is adjusted to a prescribed amount.  
 Alternatively, injection may also be prepared by taking the  
 5 medicament in a predetermined amount and sealing it into  
 a container for injection.

Examples of carriers that may be used for oral  
 preparations include those conventionally used in  
 pharmaceutical preparations such as starch, mannitol,  
 10 crystalline cellulose, carboxymethyl cellulose, etc.  
 Examples of carriers for injection are distilled water,  
 physiological saline, a glucose solution, fluid  
 supplementation, etc. Other additives conventionally used  
 for pharmaceutical preparations in general may also be  
 15 added appropriately to the preparations.

The present invention further provides the following  
 features.

(1) A method for analysis which comprises using at least  
 two cultured cell lines derived from human liver capable  
 20 of stably expressing at least one of CYP1A1, CYP1A2, CYP2A6,  
 CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4,  
 said analysis being for (a) an enzyme that participates in  
 the metabolism of xenobiotics and/or endogenous substrates,  
 (b) a metabolic pathway of xenobiotics and/or endogenous  
 25 substrates, (c) a chemical structure of the metabolite of  
 xenobiotics and/or endogenous substrates, (d) inhibition  
 of the metabolizing enzyme for xenobiotics and/or  
 endogenous substrates, (e) an accelerated activity of the  
 metabolizing enzyme for xenobiotics and/or endogenous  
 30 substrates, (f) cytotoxicity by the metabolism of  
 xenobiotics and/or endogenous substrates, (g)  
 genotoxicity by the metabolism of xenobiotics and/or  
 endogenous substrates, (h) carcinogenicity by the  
 metabolism of a xenobiotic and/or endogenous substrate, (i)  
 35 mutagenicity by the metabolism of xenobiotics and/or

10000158-102501

endogenous substrates, (j) hepatotoxicity by the metabolism of xenobiotics and/or endogenous substrates, or (k) xenobiotics and/or endogenous substrates that act on the liver.

5 (2) A method for preparation of the metabolite of xenobiotics and/or endogenous substrates, which comprises using at least two cultured cell lines from human liver capable of stably expressing at least one of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and  
10 CYP3A4.

(3) A method for screening a substance which comprises using at least two cultured cell lines from human liver capable of stably expressing at least one of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and  
15 CYP3A4, said substance being (a) a substance capable of inhibiting the metabolizing enzyme for xenobiotics and/or endogenous substrates, (b) a substance capable of accelerating an activity of the metabolizing enzyme for xenobiotics and/or endogenous substrates, (c) a substance  
20 capable of expressing cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (d) a substance capable of expressing genotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (e) a substance capable of expressing carcinogenicity by the metabolism of  
25 xenobiotics and/or endogenous substrates, (f) a substance capable of expressing mutagenicity by the metabolism of xenobiotics and/or endogenous substrates, (g) a substance capable of expressing hepatotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (h) xenobiotics  
30 and/or endogenous substrates which act on the liver, or (i) a substance capable of acquiring a new physiological activity or increasing or decreasing the inherent physiological activity, through the metabolism of xenobiotics and/or endogenous substrates.

35 (4) A compound or a salt thereof (pharmaceutical

10009158-102504

composition), which is obtainable using the method according to (3).

The following terms are used to refer to the same meanings as given hereinabove: the term "a method for screening (a) an enzyme that participates in the metabolism of xenobiotics and/or endogenous substrates, (b) a metabolic pathway of xenobiotics and/or endogenous substrates, (c) a chemical structure of the metabolite of xenobiotics and/or endogenous substrates, (d) inhibition of the metabolizing enzyme for xenobiotics and/or endogenous substrates, (e) an accelerated activity of the metabolizing enzyme for xenobiotics and/or endogenous substrates, (f) cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (g) genotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (h) carcinogenicity by the metabolism of a xenobiotic and/or endogenous substrate, (i) mutagenicity by the metabolism of xenobiotics and/or endogenous substrates, (j) hepatotoxicity by the metabolism of xenobiotics and/or endogenous substrates, or (k) xenobiotics and/or endogenous substrates that act on the liver," the term "a method for preparation of the metabolite of xenobiotics and/or endogenous substrates," the term "a method for screening (a) a substance capable of inhibiting the metabolizing enzyme for xenobiotics and/or endogenous substrates, (b) a substance capable of accelerating an activity of the metabolizing enzyme for xenobiotics and/or endogenous substrates, (c) a substance capable of expressing cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (d) a substance capable of expressing genotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (e) a substance capable of expressing carcinogenicity by the metabolism of xenobiotics and/or endogenous substrates, (f) a substance capable of expressing mutagenicity by the metabolism of

10000150-10001

xenobiotics and/or endogenous substrates, (g) a substance  
 capable of expressing hepatotoxicity by the metabolism of  
 xenobiotics and/or endogenous substrates, (h) xenobiotics  
 and/or endogenous substrates which act on the liver, or (i)  
 5 a substance capable of acquiring a new physiological  
 activity or increasing or decreasing the inherent  
 physiological activity, through the metabolism of  
 xenobiotics and/or endogenous substrates" as well as the  
 terms "a compound or its salt (pharmaceutical composition),  
 10 which is obtainable by the method for screening (a) a  
 substance capable of inhibiting the metabolizing enzyme for  
 xenobiotics and/or endogenous substrates, (b) a substance  
 capable of accelerating an activity of the metabolizing  
 enzyme for xenobiotics and/or endogenous substrates, (c)  
 15 a substance capable of expressing cytotoxicity by the  
 metabolism of xenobiotics and/or endogenous substrates,  
 (d) a substance capable of expressing genotoxicity by the  
 metabolism of xenobiotics and/or endogenous substrates,  
 (e) a substance capable of expressing carcinogenicity by  
 20 the metabolism of xenobiotics and/or endogenous substrates,  
 (f) a substance capable of expressing mutagenicity by the  
 metabolism of xenobiotics and/or endogenous substrates,  
 (g) a substance capable of expressing hepatotoxicity by the  
 metabolism of xenobiotics and/or endogenous substrates,  
 25 (h) xenobiotics and/or endogenous substrates which acts on  
 the liver, or (i) a substance capable of acquiring a new  
 physiological activity or increasing or decreasing the  
 inherent physiological activity, through the metabolism of  
 xenobiotics and/or endogenous substrates."

30 The method for analysis, the method for preparation  
 and the method for screening, described above, which  
 comprises "using at least two cultured cell lines derived  
 from human liver capable of stably expressing at least one  
 of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19,  
 35 CYP2D6, CYP2E1 and CYP3A4" enable to achieve the analysis,

10009150-10501  
105207-85160007

preparation and screening in a way closer to in vivo, than in the case of using the cell line which expresses only one enzyme of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.

5 When two kinds or more of the cell lines are used, the respective cell lines may be used at the same time, or independently followed by comparison between the respective results in the analysis, preparation and screening.

10 The cell lines Hepc/3A4.5, Hepc/2E1.3-8, Hepc/2C9.1, Hepc/2C8.46, Hepc/1A2.9 and Hepc/1A1.4, which were obtained in EXAMPLES later described, have been deposited with Institute for Fermentation (IFO) at 2-17-85, Juso Honcho, Yodogawa-ku, Osaka, as deposit numbers IFO 50502, 15 50503, 50504, 50505, 50506 and 50507, respectively, since February 10, 1999, and with the Ministry of International Trade and Industry, Agency of Industrial Science and Technology, National Institute of Bioscience and Human Technology (NIBH) at 1-1-3, Tsukuba Higashi, Tsukuba-shi, 20 Ibaraki, as deposit numbers FERM BP-7120, FERM BP-7121, FERM BP-7122, FERM BP-7123, FERM BP-7124 and FERM BP-7125, respectively, since April 12, 2000. Hepc/2B6.68 and Hepc/2D6.39 have been deposited with Institute for Fermentation (IFO) at 2-17-85, Juso Honcho, Yodogawa-ku, 25 Osaka, as deposit numbers IFO 50508 and 50509, respectively, since February 15, 1999, and with the Ministry of International Trade and Industry, Agency of Industrial Science and Technology, National Institute of Bioscience and Human Technology (NIBH) at 1-1-3, Tsukuba Higashi, 30 Tsukuba-shi, Ibaraki, as deposit numbers FERM BP-7126 and FERM BP-7127, respectively, since April 12, 2000. Hepc/2A6L.9 and Hepc/2C19.12 have been deposited with Institute for Fermentation (IFO) at 2-17-85, Juso Honcho, Yodogawa-ku, Osaka, as deposit numbers IFO 50511 and 50512, 35 respectively, since February 15, 1999, and with the

10005150-102501  
T0520T\* 0516000T

Ministry of International Trade and Industry, Agency of Industrial Science and Technology, National Institute of Bioscience and Human Technology (NIBH) at 1-1-3, Tsukuba Higashi, Tsukuba-shi, Ibaraki, as deposit numbers FERM  
 5 BP-7128 and FERM BP-7129, respectively, since April 12, 2000.

#### EXAMPLES

Hereinafter EXAMPLES of the present invention are  
 10 described in detail but the invention is not deemed to be limited thereto. For genetic engineering, conventional procedures were conducted following the manual described in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press), etc., unless  
 15 otherwise indicated.

#### EXAMPLE 1

Cloning of DNA fragments encoding cytochromes P450 and preparation of expression vector

20 DNA fragments encoding human cytochromes P450 were cloned from complementary DNA (cDNA) library derived from human adult liver, using the established polymerase chain reaction (hereinafter PCR) method. The cDNA sequences of human cytochromes P450 to be cloned are available from the  
 25 database of GeneBank. The accession numbers in GeneBank are KO3191 for CYP1A1; M55053 or M38504 for CYP1A2; M33318 or M33316 for CYP2A6; M29874 or J02864 for CYP2B6; M17397 or J03472 for CYP2C8; M61857 or J05326 for CYP2C9; M61854 or J05326 for CYP2C19; X08006 or Y00300 for CYP2D6; J02625 for  
 30 CYP2E1 and J04449 for CYP3A4.

Each of the cloned cDNAs was inserted into pcDNA3.1(+) vector (Invitrogen Co.) CMV (cytomegalovirus) downstream its enhancer promoter along with the direction in which the promoter could function, to obtain 1A1/pcDNA3.1(+)   
 35 inserted with CYP1A1, 1A2/pcDNA3.1(+) inserted with CYP1A2,

105201-8516001

2A6/pcDNA3.1(+) inserted with CYP2A6, 2B6/pcDNA3.1(+) inserted with CYP2B6, 2C8/pcDNA3.1(+) inserted with CYP2C8, 2C9/pcDNA3.1(+) inserted with CYP2C9, 2C19/pcDNA3.1(+) inserted with CYP2C19, 2D6/pcDNA3.1(+) inserted with CYP2D6, 2E1/pcDNA3.1(+) inserted with CYP2E1 and 3A4/pcDNA3.1(+) inserted with CYP3A4, respectively.

## EXAMPLE 2

Screening of cells capable of expressing the high activity of cytochromes P450

HepG2 was maintained in DMEM (Dulbecco's Modified Eagle's medium) supplemented with 10% FCS (fetal calf serum; Bio Whittaker). HepG2 was inoculated on a 60 mm dish and grown 50-60% confluent in a CO<sub>2</sub> incubator followed by transfection of 2 µg of 1A1/pcDNA3.1(+), 1A2/pcDNA3.1(+), 2A6/pcDNA3.1(+), 2B6/pcDNA3.1(+), 2C8/pcDNA3.1(+), 2C9/pcDNA3.1(+), 2C19/pcDNA3.1(+), 2D6/pcDNA3.1(+), 2E1/pcDNA3.1(+) or 3A4/pcDNA3.1(+) using lipofectamine reagent (GIBCO BRL). After incubating in 10% FCS-supplemented DMEM medium for 2 days, a fresh DMEM medium supplemented with 500 µg/ml G418 (GIBCO BRL) and 10% FCS was replaced for the medium. A fresh medium was replaced every 3 or 4 days to effect cloning of G418-resistant strains. The resulting G418-resistant strains were maintained in DMEM medium supplemented with 200 µg/ml G418 (GIBCO BRL) and 10% FCS. Each of the G418-resistant strains was assayed for the activity of cytochromes P450 by the method described below. Cell lines showing a high activity were measured and cells that expressed the high activity were selected.

(1) Assay for activity of CYP1A1- and CYP1A2-expressing cells and selection of cells expressing high activity:

Ethoxyresorufin (Molecular Probes) was diluted with DMSO (dimethyl sulfoxide; Wako Junyaku K.K.) in a concentration of 2 mM. Then the dilution was further diluted

105207 8515001

Sul  
Al<sub>13</sub>  
15

to 500  $\mu$ M with Phenol Red-free DMEM medium (GIBCO BRL) supplemented with 2% FCS (Bio Whittaker).

CYP1A1- or CYP1A2-expressing cells were inoculated on a 12-well plate (Falcon) and incubated in a CO<sub>2</sub> incubator so as to become confluent. After incubation, the medium was suctioned and cells adhered to the plate were washed with Phenol Red-free DMEM medium. Subsequently, ethoxyresorufin previously diluted to 500  $\mu$ M was added in 500  $\mu$ l/well. After reacting at 37°C in the dark, the reaction solution was recovered from each well. After 1800  $\mu$ l of methanol (Wako Junyaku K.K.) was added to 300  $\mu$ l of the reaction solution and insoluble matters were removed by centrifugation, fluorescent intensity was measured at an excited wavelength of 350 nm and a fluorescence wavelength of 586 nm using a spectrofluorometer to quantify the resorufin formed. The product purchased from Molecular Probes was used as the standard substance for resorufin (Molecular Probes).

From the CYP1A1 or CYP1A2 activity-expressing strains, strains Hepc/1A1.4 and Hepc/1A2.9 were selected, respectively, as CYP1A1- and CYP1A2-expressing strains in high levels.

(2) Assay for activity of CYP2A6-expressing cells and selection of cells expressing high activity:

Coumarin (Wako Junyaku K.K.) was diluted with methanol (Wako Junyaku K.K.) in a concentration of 50 mM. Next, the dilution was further diluted to 500  $\mu$ M with Phenol Red-free DMEM medium (GIBCO BRL) supplemented with 2% FCS (Bio Whittaker).

CYP2A6-expressing cells were inoculated on a 12-well plate (Falcon) and incubated in a CO<sub>2</sub> incubator so as to become confluent. After incubation, the medium was suctioned and cells adhered to the plate were washed with Phenol Red-free DMEM medium. Subsequently, coumarin previously diluted to 500  $\mu$ M was added in 500  $\mu$ l/well. After

Sub A25  
5 reacting at 37°C, the reaction solution was recovered from each well. The reaction solution was diluted to 10-fold with 0.1M Tris-HCl (pH 7.4) and fluorescent intensity was measured at an excited wavelength of 390 nm and a fluorescence wavelength of 440 nm using a spectrofluorometer to quantify 7-hydroxycoumarin formed. The product purchased from Extrasynthese was used as the standard substance for 7-hydroxycoumarin.

10 From the CYP2A6 activity-expressing strains, Hepc/2A6L.9 was selected as CYP2A6-expressing strain in a high level.

(3) Assay for activity of CYP2B6-expressing cells and selection of cells expressing high activity:

15 7-Ethoxycoumarin (Molecular Probes) was diluted with DMSO (Wako Junyaku K.K.) in a concentration of 10 mM. Next, the dilution was further diluted to 500 µM with Phenol Red-free DMEM medium (GIBCO BRL) supplemented with 2% FCS (Bio Whittaker).

20 CYP2B6-expressing cells were inoculated on a 12-well plate (Falcon) and incubated in a CO<sub>2</sub> incubator so as to become confluent. After incubation, the medium was suctioned and cells adhered to the plate were washed with Phenol Red-free DMEM medium. Subsequently, 7-ethoxycoumarin previously diluted to 500 µM was added in  
25 500 µl/well. After reacting at 37°C, the reaction solution was recovered from each well. The reaction solution was diluted to 10-fold with 0.1M Tris-HCl (pH 7.4) and fluorescent intensity was measured at an excited wavelength of 390 nm and a fluorescence wavelength of 440 nm, using  
30 a spectrofluorometer (Hitachi Spectrofluorometer F-2000) to quantify 7-hydroxycoumarin formed. The product purchased from Extrasynthese was used as the standard substance for 7-hydroxycoumarin.

Sub A22  
35 From the CYP2B6 activity-expressing strains, Hepc/2B6.68 was selected as CYP2B6-expressing strain in a

105201 051501 102501

high level.

(4) Assay for activity of CYP2C8-expressing cells and selection of cells expressing high activity:

5 Taxol (ULTRAFINE Chemicals) was diluted with methanol (Wako Junyaku K.K.) in a concentration of 10 mM. Next, the dilution was further diluted to 30  $\mu$ M with Phenol Red-free DMEM medium (GIBCO BRL) supplemented with 2% FCS (Bio Whittaker).

10 CYP2C8-expressing cells were inoculated on a 12-well plate (Falcon) and incubated in a CO<sub>2</sub> incubator so as to become confluent. After incubation, the medium was suctioned and cells adhered to the plate were washed with Phenol Red-free DMEM medium. Subsequently, taxol diluted previously to 30  $\mu$ M was added in 500  $\mu$ l/well. After reacting at 37°C, the reaction solution was recovered from each well. After an equal volume of acetonitrile (Wako Junyaku K.K.) was added to and mixed with the reaction solution, insoluble matters were removed by centrifugation. 6 $\alpha$ -Hydroxypaclitaxel formed in the reaction solution was  
15  
20 quantified on HPLC.

Capcell Pak C18 AG120 (5  $\mu$ m, 4.6 mm $\phi$  x 250 mm, Shiseido) was used as a column. As a mobile phase, 40% acetonitrile (reagent for HPLC, Wako Junyaku K.K.) was used. After injecting 40  $\mu$ l of the reaction solution, elution was  
25 conducted at a flow rate of 1.0 ml/min. and a column temperature of 40°C, using the mobile phase described above. Taxol and 6 $\alpha$ -hydroxypaclitaxel were detected at 230 nm (absorbance). As the standard substance, 40  $\mu$ l each of 10  $\mu$ M taxol and 5  $\mu$ M 6 $\alpha$ -hydroxypaclitaxel (Gentest) were  
30 injected.

From the CYP2C8 activity-expressing strains, Hepc/2C8.46 was selected as CYP2C8-expressing strain in a high level.

(5) Assay for activity of CYP2C9-expressing cells and  
35 selection of cells expressing high activity:

10009158-102501

Suk  
A23

Sub  
A 24

Inertsil ODS-2 (5  $\mu\text{m}$ , 4.6 mm $\phi$  x 150 mm, GL Science) was used as a column. As a mobile phase, a 72:28 v/v mixture of 10 mM acetate buffer (pH 4.3) and acetonitrile (reagent for HPLC, Wako Junyaku K.K.) was used. After injecting 40  $\mu\text{l}$  of the reaction solution, elution was conducted at a flow rate of 1.0 ml/min. and a column temperature of 40°C, using the mobile phase described above. Tolbutamide and hydroxytolbutamide were detected at 230 nm (absorbance). As the standard substance, 40  $\mu\text{l}$  each of 100  $\mu\text{M}$  tolbutamide and 10  $\mu\text{M}$  hydroxytolbutamide (Sumitomo Chemical Analysis Center) were injected.

(6) Assay for activity of CYP2C19-expressing cells and selection of cells expressing high activity:

(S)-Mephenytoin (Sumitomo Chemical Analysis Center)  
35 was diluted with methanol (Wako Junyaku K.K.) in a

concentration of 10 mM. Next, the dilution was further diluted to 100  $\mu$ M with Phenol Red-free DMEM medium (GIBCO BRL) supplemented with 2% FCS (Bio Whittaker).

5 CYP2C19-expressing cells were inoculated on a 12-well plate (Falcon) and incubated in a CO<sub>2</sub> incubator so as to become confluent. After incubation, the medium was suctioned and cells adhered to the plate were washed with Phenol Red-free DMEM medium. Subsequently, mephenytoin previously diluted to 100  $\mu$ M was added in 500  $\mu$ l/well. After reacting at 37°C, the reaction solution was recovered from each well. After an equal volume of acetonitrile (Wako Junyaku K.K.) was added to and mixed with the reaction solution, insoluble matters were removed by centrifugation. 4'-Hydroxymephenytoin formed in the reaction solution was  
10 quantified on HPLC.

Capcell Pak C18 AG120 (5  $\mu$ m, 4.6 mm $\phi$  x 250 mm, Shiseido) was used as a column. As a mobile phase, a 74:26 v/v mixture of 0.05 M KH<sub>2</sub>PO<sub>4</sub> (pH 4.0) and acetonitrile (reagent for HPLC, Wako Junyaku K.K.) was used. After injecting 40  $\mu$ l of the reaction solution, elution was conducted at a flow rate of 0.8 ml/min. and a column temperature of 40°C, using the mobile phase described above. (S)-Mephenytoin and 4'-hydroxymephenytoin were detected at 204 nm (absorbance). As the standard substance, 40  $\mu$ l each of 50  $\mu$ M (S)-  
20 mephenytoin and 5  $\mu$ M hydroxymephenytoin (Sumitomo Chemical Analysis Center) were injected.

From the CYP2C19 activity-expressing strains, Hepc/2C19.12 was selected as CYP2C19-expressing strain in a high level.

30 (7) Assay for activity of CYP2D6-expressing cells and selection of cells expressing high activity:

Bufralol (Sumitomo Chemical Analysis Center) was diluted with distilled water in a concentration of 20 mM. Next, the dilution was further diluted to 200  $\mu$ M with Phenol Red-free DMEM medium (GIBCO BRL) supplemented with 2% FCS  
35

T0520T" 85T000T

Sub  
A25/

(Bio Whittaker).

5 CYP2D6-expressing cells were inoculated on a 12-well plate (Falcon) and incubated in a CO<sub>2</sub> incubator so as to become confluent. After incubation, the medium was suctioned and cells adhered to the plate were washed with Phenol Red-free DMEM medium. Subsequently, bufuralol previously diluted to 200  $\mu$ M was added in 500  $\mu$ l/well. After reacting at 37°C, the reaction solution was recovered from each well and 1'-hydroxybufuralol formed in the reaction solution was quantified on HPLC.

10 Inertsil ODS (5  $\mu$ m, 4.6 mm $\phi$  x 250 mm, GL Science) was used as a column. As a mobile phase, 30% acetonitrile (reagent for HPLC, Wako Junyaku K.K.) containing 1 mM perchloric acid (Wako Junyaku K.K.) was used. The reaction solution was diluted to 100-fold with distilled water and 40  $\mu$ l of the reaction solution was injected, followed by elution at a flow rate of 1.0 ml/min. and a column temperature of 50°C, using the mobile phase described above. Bufuralol and hydroxybufuralol were detected at an excited wavelength of 252 nm and at a fluorescence wavelength of 302 nm. As the standard substance, 40  $\mu$ l each of 100 pM bufuralol and 10 pM 1'-hydroxybufuralol (Sumitomo Chemical Analysis Center) were injected.

25 From the CYP2D6 activity-expressing strains, Hepc/2D6.39 was selected as CYP2D6-expressing strain in a high level.

(8) Assay for activity of CYP2E1-expressing cells and selection of cells expressing high activity:

30 p-Nitrophenol (Wako Junyaku K.K.) was diluted with DMSO (Wako Junyaku K.K.) in a concentration of 2 mM. Next, the dilution was further diluted to 500  $\mu$ M with Phenol Red-free DMEM medium (GIBCO BRL) supplemented with 2% FCS (Bio Whittaker).

35 2E1-expressing cells were inoculated on a 12-well plate (Falcon) and incubated in a CO<sub>2</sub> incubator so as to

become confluent. After incubation, the medium was  
 suctioned and cells adhered to the plate were washed with  
 Phenol Red-free DMEM medium. Subsequently, p-nitrophenol  
 previously diluted to 500  $\mu$ M was added in 500  $\mu$ l/well. After  
 reacting at 37°C, the reaction solution was recovered from  
 each well. To 100  $\mu$ l of the reaction solution 50  $\mu$ l of NaOH  
 (Wako Junyaku K.K.) was added, and insoluble matters were  
 removed by centrifugation. By measuring absorbance at 540  
 nm - 620 nm, 4-nitrocatechol formed was quantified. 4-  
 Nitrocatechol purchased from Wako Junyaku K.K. was used as  
 the standard substance.

From the CYP2E1 activity-expressing strains,  
 Hepc/2E1.3-8 was selected as CYP2E1-expressing strain in  
 a high level.

(9) Assay for activity of CYP3A4-expressing cells and  
 selection of cells expressing high activity:

Testosterone (Wako Junyaku K.K.) was diluted with  
 methanol (Wako Junyaku K.K.) in a concentration of 10 mM.  
 Next, the dilution was further diluted to 100  $\mu$ M with Phenol  
 Red-free DMEM medium (GIBCO BRL) supplemented with 2% FCS  
 (Bio Whittaker).

CYP3A4-expressing cells were inoculated on a 12-well  
 plate (Falcon) and incubated in a CO<sub>2</sub> incubator so as to  
 become confluent. After incubation, the medium was  
 suctioned and cells adhered to the plate were washed with  
 Phenol Red-free DMEM medium. Subsequently, testosterone  
 previously diluted to 100  $\mu$ M was added in 500  $\mu$ l/well. After  
 reacting at 37°C, the reaction solution was recovered from  
 each well. After an equal volume of acetonitrile (Wako  
 Junyaku K.K.) was added to and mixed with the reaction  
 solution, insoluble matters were removed by centrifugation.  
 6 $\beta$ -Hydroxytestosterone formed in the reaction solution was  
 quantified on HPLC.

Capcell Pak C18 AG120 (5  $\mu$ m, 4.6 mm $\phi$  x 250 mm, Shiseido)  
 was used as a column. A solution of 40% methanol (reagent

for HPLC, Wako Junyaku K.K.) and 3.5% acetonitrile (reagent  
for HPLC, Wako Junyaku K.K.), and a solution of 40% methanol  
and 20 acetonitrile were used as solution A and solution  
B, respectively. A program was made up to set for a linear  
5 gradient of 0-100% solution B in 0-20 minutes, 100% solution  
B in 20-30 minutes and since then 100% solution. By  
injecting 40  $\mu$ l of the reaction solution, elution was  
performed at a flow rate of 1.0 ml/min. and a column  
temperature of 40°C, using the mobile phase described above.  
10 Testosterone and 6 $\beta$ -hydroxytestosterone were detected at  
254 nm (absorbance). As the standard substance, 40  $\mu$ l each  
of 50  $\mu$ M testosterone and 5  $\mu$ M 6 $\beta$ -hydroxytestosterone  
(Sumitomo Chemical Analysis Center) were injected.

From the CYP3A4 activity-expressing strains,  
15 Hepc/3A4.5 was selected as CYP3A4-expressing strain in a  
high level.

### EXAMPLE 3

Kinetic analysis of cytochromes P450-expressing strains in  
20 a high level

Following the assay for enzyme activity described in  
EXAMPLE 2, a variety of substrates were acted on the  
cytochromes P450-expressing strains in a high level, which  
were obtained in EXAMPLE 2. A Lineweaver-Burk plot was  
25 prepared, and Km and Vmax values were obtained from the X-  
and Y-intercepts. The results are shown in TABLE 1.

30

35

10005158-102501

TABLE 1.

CYP molecules	Transformant	Enzyme activity	Rate Constant	
			Km( $\mu$ M)	Vmax(pmol/min/mg)
CYP1A1	Hepc/1A1.4	7-ethoxyresorufin O-deethylase activity	0.25	56
CYP1A2	Hepc/1A2.9	7-ethoxyresorufin O-deethylase activity	0.72	1.6
CYP2A6	Hepc/2A6L.9	Coumarin 7-hydroxylase activity	11.1	412
CYP2B6	Hepc/2B6.68	7-ethoxycoumarin O-deethylase activity	81	80
CYP2C8	Hepc/2C8.46	Taxol 6-hydroxylase activity	7.4	0.009
CYP2C9	Hepc/2C9.1	Tolbutamide 4-hydroxylase activity	77	23
CYP2C19	Hepc/2C19.12	(S)-mephenytoin 4'-hydroxylase activity	8.26	140
CYP2D6	Hepc/2D6.39	Bufuralol 1'-hydroxylase activity	17	14
CYP2E1	Hepc/2E1.3-8	p-nitrophenol hydroxylase activity	88	120
CYP3A4	Hepc/3A4.5	Testosterone 6 $\beta$ -hydroxylase activity	96	71

## EXAMPLE 4

Activation of the metabolism of acetaminophen by

105207 85160001

CYP2E1-expressing cells and expression of cytotoxicity  
Method:

1. MTT Assay

HepG2 or CYP2E1-expressing cells (Hepc/2E1.3-8) (4 x  
5 10<sup>5</sup> cells/ml) were incubated with acetaminophen (Wako  
Junyaku K.K.) diluted to a given concentration in DMEM  
medium supplemented with 5% FCS in a CO<sub>2</sub> incubator. In the  
test to terminate glutathione conjugation, L-Buthionine  
[S,R]-Sulfoximine (BSO, Sigma) was added to the medium in  
10 a final concentration of 100 µM. After incubation for 4 days,  
20 µl of a solution of 3-(4,5-dimethyl-2-thiazolyl)-  
2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma) adjusted  
to 1 mg/ml with PBS (Flow) was added to each well followed  
by incubation at 37°C for 3 hours. Next, 100 µl of 0.01N  
15 HCl solution containing 10% SDS was added to each well.  
After incubation at 37°C overnight, absorbance was measured  
at 590 nm. The results are shown in FIG. 1.

2. Determination of LDH (lactate dehydrogenase) leakage

Two plates each with the same design as in the MTT assay  
20 were prepared (for determination of LDH activity in the  
culture supernatant and for determination of LDH activity  
in the culture supernatant + LDH activity in the cells).  
After incubating for 3 days in a CO<sub>2</sub> incubator, 10 µl of  
the supernatant was taken from each well of one plate (for  
25 determination of LDH activity in the supernatant),  
transferred to another 96-well plate, and 40 µl of distilled  
water was further added. On the other hand, 10 µl of 10%  
Triton X100 (Wako Junyaku K.K.) was added to each well of  
another plate (for determination of LDH activity in the  
30 culture supernatant + LDH activity in the cells), followed  
by shaking and incubation at 37°C for 45 minutes. After  
centrifuging at 1500 rpm for 5 minutes, 10 µl of the  
supernatant was taken from each well, transferred to  
another 96-well plate, and 40 µl of distilled water was  
35 further added. The LDH activity of each well in these plates

was measured using Cytotox 96 Non-Radioactive Cytotoxicity Assay Kit (Promega). Multiscanning MS-UV was used for the measurement of absorbance. A ratio of the LDH activity in the supernatant to (the LDH activity in the supernatant + the LDH activity in the cells) was made an LDH leakage rate. The results are shown in FIG. 2.

### Results

Results: see FIGS. 1 and 2

When acetaminophen is present in a large quantity, exhaustion of activated sulfate or a rate-determining factor occurs. While glucuronide conjugation occurs in large quantities, the reaction rate is limiting and thus, N-hydroxylation is caused by P450. The activated intermediate N-acetylbenzoquinonimide formed from the N-hydroxylated product is generally detoxified through conjugation with glutathione. It is known, however, that exhaustion of glutathione results in covalent binding of the activated intermediate with macromolecular components in the liver to cause necrosis of liver cells (M.J.J. Ronis et al., Cytochromes P450 Metabolic and Toxicological Aspects, pages 211-240, ed. by C. Ioannides et al., CRC Press, 1996).

Acetaminophen caused a slight leakage of LDH from HepG2 and Hepc/2E1.3-8 cells. When glutathione present in the cells was exhausted there in the presence of BSO, sensitivity to acetaminophen was enhanced approximately 4 times in Hepc/2E1.3-8 cells, and LDH was concentration-dependently leaked at a lower level. Any effect expected in the presence of BSO was not noted with HepG2 (FIG. 2). Turning to the MTT assay method, acetaminophen caused a slight decrease of the MTT activity in HepG2 and Hepc/2E1.3-8 cells. In the presence of BSO, an increased sensitivity to acetaminophen was noted in Hepc/2E1.3-8 cells, with concentration-dependently lowering of the MTT

activity at a lower concentration (FIG. 1). While acetaminophen is metabolized by the CYP2E1 activity expressed by Hepc/2E1.3-8, the metabolites are detoxified through glutathione conjugation. However, when  
5 glutathione is exhausted through the action of BSO, it is considered that cytotoxicity would be exhibited by the metabolic intermediate formed. It is demonstrated that Hepc/2E1.3-8 has not only the CYP2E1 activity but also the glutathione transferase activity.

10

#### EXAMPLE 5

Activation of the metabolism of benzanthrane by CYP1A1-expressing cells and expression of cytotoxicity  
Method:

15 CYP1A1-expressing cells (Hepc/1A1.4) ( $4 \times 10^5$  cells/ml) were incubated with benzanthrane (Sigma) diluted to a given concentration in DMEM medium supplemented with 5% FCS in a CO<sub>2</sub> incubator. After incubation for 4 days, 20  $\mu$ l of a MTT (Sigma) solution  
20 adjusted to 1 mg/ml with PBS (Flow) was added to each well followed by incubation at 37°C for 3 hours. Next, 100  $\mu$ l of 0.01N HCl solution containing 10% SDS was added to each well. After incubation at 37°C overnight, absorbance was measured at 590 nm. The results are shown in FIG. 3.

25

Results: see FIG. 3

It is known that benzanthrane is metabolized by the CYP1A1 activity and the metabolic intermediate formed  
30 causes cytotoxicity, carcinogenesis and mutagenesis (K. Kawajiri, et al., Cytochromes P450 Metabolic and Toxicological Aspects, pages 77-97, ed. by C. Ioannides, et al., CRC Press, 1996). A more potent reduction in the MTT activity was noted in Hepc/1A1.4 cells than in HepG2,  
35 dependently with the concentration of benzanthrane. This

reveals that benzanthrane was metabolized by the CYP1A1 activity expressed by Hepc/1A1.4 cells, and cytotoxicity was exhibited by the metabolic intermediate.

5   EXAMPLE 6

Activation of the metabolism of cyclophosphamide by CYP2B6-expressing cells and expression of cytotoxicity  
Method:

1. MTT Assay

10       CYP2B6-expressing cells (Hepc/2B6.68) ( $4 \times 10^5$  cells/ml) were incubated with cyclophosphamide (Sigma) diluted to a given concentration in DMEM medium supplemented with 5% FCS in a CO<sub>2</sub> incubator. After incubation for 4 days, 20  $\mu$ l of a MTT (Sigma) solution  
15       adjusted to 1 mg/ml with PBS (Flow) was added to each well followed by incubation at 37°C for 3 hours. Next, 100  $\mu$ l of 0.01N HCl solution containing 10% SDS was added to each well. After incubation at 37°C overnight, absorbance was measured at 590 nm. The results are shown in FIG. 4.

20   2. Determination of LDH leakage

Two plates each with the same design as in the MTT assay were prepared (for determination of LDH activity in the culture supernatant and for determination of LDH activity in the culture supernatant + LDH activity in the cells).  
25       After incubating for 4 days in a CO<sub>2</sub> incubator, 10  $\mu$ l of the supernatant was taken from each well of one plate (for determination of LDH activity in the supernatant), transferred to another 96-well plate, and 40  $\mu$ l of distilled water was further added. On the other hand, 10  $\mu$ l of 10%  
30       Triton X100 was added to each well of another plate (for determination of LDH activity in the culture supernatant + LDH activity in the cells), followed by shaking and incubation at 37°C for 45 minutes. After centrifuging at 1500 rpm for 5 minutes, 10  $\mu$ l of the supernatant was taken  
35       from each well, transferred to another 96-well plate, and

40  $\mu$ l of distilled water was further added. The LDH activity of each well in these plates was measured using Cytotox 96 Non-Radioactive Cytotoxicity Assay Kit (Promega). Multiscanning MS-UV was used for the measurement of absorbance. A ratio of the LDH activity in the supernatant to (the LDH activity in the supernatant + the LDH activity in the cells) was made an LDH leakage rate. The results are shown in FIG. 5.

### Results

Results: see FIGS. 4 and 5

It is considered that after cyclophosphamide is hydrolyzed at the 4-position, phosphoramidate or acrolein formed by non-enzymatic degradation would act as an alkylating agent to cause hepatic cytotoxicity triggered by covalent binding to macromolecular components in liver cells (K. H. Thomas, et al., Cancer Research, vol. 53, pages 5629-5637, 1993). Cyclophosphamide caused a leakage of LDH in Hepc/2B6.68 cells concentration-dependently in the concentration up to 2 mM and then reached the plateau at the following concentrations. Cyclophosphamide was slightly cytotoxic also in HepG2 (FIG. 4). Turning to the MTT assay method, cyclophosphamide caused a slight decrease of the MTT activity concentration-dependently in Hepc/2B6.68 cells (FIG. 5). Cyclophosphamide was metabolized by the CYP2B6 activity, and the metabolic intermediate formed showed cytotoxicity.

### EXAMPLE 7

#### Analysis of inhibition of CYP3A4 activity

##### Method:

Hepc/3A4.5 cells were inoculated on a 12-well plate and incubated so as to become confluent. After washing twice with Phenol Red-free DMEM medium, various concentrations of ketoconazole (Biomol Research Lab.) diluted with 500  $\mu$ l

10000150-100001

A

10

15

20

25

30

35

of Phenol Red-free DMEM medium containing 2% FCS was added followed by incubation at 37°C for 4 hours. After washing twice with Phenol Red-free DMEM medium, testosterone in a final cocentration of 100  $\mu$ M diluted with 500  $\mu$ l of Phenol Red-free DMEM medium containing 2% FCS was added. After incubation at 37°C for an hour, the supernatant was recovered. After an equal volume of acetonitrile was added to and mixed with the reaction solution, insoluble matters were removed by centrifugation to provide for a test specimen. The thus obtained specimen was quantified for 6 $\beta$ -hydroxy-testosterone on HPLC by the method described in EXAMPLE 2 (9).

The experimental results are shown in terms of relative value when the amount of 6 $\beta$ -hydroxy-testosterone without adding any drug was made 100% (FIG. 6).

Ketoconazole is known to be a strong CYP3A4 inhibitor (S. J. Baldwin, et al., Xenobiotica, vol. 25, pages 261-270, 1995). The CYP3A4 activity (testosterone 6 $\beta$ -hydroxylation activity) was inhibited in Hepc/3A4.5 cells dependently on the concentration of ketoconazole (FIG. 6). IC<sub>50</sub> of ketoconazole was 0.3  $\mu$ M or less.

#### EXAMPLE 8

##### Analysis of CYP2E1 activity induction

##### Method:

Hepc/2E1.3-8 cells ( $5 \times 10^5$  cells/ml) were inoculated with ethanol and DMSO (dimethylsulfoxide)(Wako Junyaku K.K.) diluted with DMEM medium to a given concentration on a 12-well plate (Falcon) and incubated in a CO<sub>2</sub> incubator for 3 days. The medium was suctioned and the cells attached to the plate were washed with Phenol Red-free DMEM medium. Subsequently, p-nitrophenol previously diluted to 500  $\mu$ M was added in 500  $\mu$ l/well. After reacting at 37°C, the reaction solution was recovered from each well. To 100  $\mu$ l of the reaction solution 50  $\mu$ l of NaOH (Wako Junyaku K.K.)

was added, and insoluble matters were removed by centrifugation. By measuring absorbance at 540 nm - 620 nm with multi-scanning MS-UV (Labo Systems), 4-nitrocatechol formed was quantified.

5

#### Experimental results (FIG. 7)

It is reported that by adding ethanol and DMSO (dimethylsulfoxide), the enzyme activity increases and intracellular CYP2E1 is induced (M.J.J. Ronis, et al., Cytochromes P450 Metabolic and Toxicological Aspects, pages 211-240, ed. by C. Ioannides et al., CRC Press, 1996). This EXAMPLE demonstrated the same results.

4-Nitrocatechol purchased from Wako Junyaku K.K. was used as the standard substance.

15

#### INDUSTRIAL APPLICABILITY

The human hepatic carcinoma-derived cultured cell lines of the present invention, which can stably express human cytochromes P450, are useful for analysis of (a) an enzyme that participates in the metabolism of xenobiotics and/or endogenous substrates, (b) a metabolic pathway of xenobiotics and/or endogenous substrates, (c) a chemical structure of the metabolite of xenobiotics and/or endogenous substrates, (d) inhibition of the metabolizing enzyme for xenobiotics and/or endogenous substrates, (e) an accelerated activity of the metabolizing enzyme for xenobiotics and/or endogenous substrates, (f) cytotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (g) genotoxicity by the metabolism of xenobiotics and/or endogenous substrates, (h) carcinogenicity by the metabolism of a xenobiotic and/or endogenous substrate, (i) mutagenicity by the metabolism of xenobiotics and/or endogenous substrates, (j) hepatotoxicity by the metabolism of xenobiotics and/or

35

10005158-102501

endogenous substrates, or (k) xenobiotics and/or endogenous substrates that act on the liver, and for the preparation of the metabolite of xenobiotics and/or endogenous substrates.

10009150-102501  
105201 05160001